Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA To Impose Premarket Requirements On Blood Lancets

Executive Summary

Single-patient lancets will face new special controls and 510(k) submission, while multiple-patient lancets would require a PMA.

You may also be interested in...



Power Morcellation Containment Devices Placed In FDA Class II

The special controls are to include biocompatibility, sterility and performance testing, as well as physician training and warning labels.

Heightened Standards Proposed For Finger-Prick Devices

FDA issued proposed orders to remove the 510(k) exemption and establish special controls for most blood lancets, and require PMAs for one super-risky category of the finger-prick devices. The goal is to reduce infectious disease transmission.

Abbott Claims DexCom CGM Suits Renege On Tech-Sharing Agreement

Abbott says DexCom’s patent suits involve technology that was already the subject of a settlement, and raise venue questions.

Topics

UsernamePublicRestriction

Register

MT144749

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel